Structoflex

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Structoflex

Property Description
Active Ingredient Glucosamine hydrochloride (750 mg)
Manufacturer Pierre Fabre Santé (France)
Therapeutic Class Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA)
Common Use Symptomatic relief of mild to moderate knee osteoarthritis
Regulatory Status Prescription-only medicine (Rx) in certain countries

Structoflex is a prescription-only medication, manufactured by Pierre Fabre Santé, used specifically for the symptomatic relief of mild to moderate osteoarthritis (OA) of the knee in adults. Its single active component is Glucosamine hydrochloride (750 mg). In many countries, the regulatory status as a prescription medicine confirms its standard of pharmaceutical quality and safety.

Glucosamine is classified as an amino sugar that naturally occurs in the body, where it serves as a crucial component in the production of cartilage—the connective tissue vital for cushioning joints—and the synovial fluid that lubricates them. The active ingredient in this specific medicine is commercially derived from the shells of marine shellfish, which is an important consideration for patient safety regarding allergies.

This medicine is officially categorized as an "Other non-steroidal anti-inflammatory and anti-rheumatic agent" (ATC code: M01AX05), but is commonly referred to as a Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA). This classification indicates that Structoflex is intended to provide gradual relief, differing from immediate-acting pain medications. Clinical research indicates that glucosamine preparations for the management of knee OA symptoms can contribute to a reduction in pain and improvement in joint function over time.

Regulatory References

  1. Glucosamine and Chondroitin for Osteoarthritis: What You Need To Know - NCCIH (NIH)

What side effects are possible with Structoflex?

Possible Side Effects and Safety Information

The safety profile for Structoflex (Glucosamine hydrochloride) is structured by officially documented adverse reactions categorized by frequency and system-organ class, as published in government regulatory documents like the Summary of Product Characteristics (SmPC). The most frequently reported effects generally involve the gastrointestinal and nervous systems.


Frequency-Classified Adverse Reactions

Adverse reactions are classified based on estimated rates of occurrence:

  • Common (may affect up to 1 in 10 people): Headache, Tiredness (fatigue), Nausea, Abdominal pain, Indigestion (dyspepsia), Diarrhoea, and Constipation.
  • Uncommon (may affect up to 1 in 100 people): Rash, Itching (pruritus), and Flushing.
  • Frequency Not Known: Reactions documented through post-marketing reports but whose true frequency cannot be estimated include Dizziness, Vomiting, Urticaria (hives), Hepatic enzyme elevation, Jaundice, and Hypercholesterolaemia.

Documented Safety Constraints

The medicine is contraindicated in individuals with a known allergy to shellfish due to the active ingredient's marine origin. Serious safety considerations include the potential for aggravated asthma symptoms in asthmatic patients and the requirement for close monitoring of blood glucose levels in patients with diabetes mellitus or impaired glucose tolerance. Furthermore, the official labeling notes the potential for an increased effect of Coumarin anticoagulants (e.g., Warfarin), requiring careful monitoring of coagulation parameters during concurrent use.

Overdose and Emergency Response

Structoflex Overdose and when to seek help

This information is based solely on officially documented regulatory reports and provides guidance on recognized overdose manifestations and required emergency actions.


Documented Overdose Manifestations

Official regulatory documents describe a range of signs and symptoms associated with Structoflex overdose. These may involve the Central Nervous System (CNS), resulting in effects like somnolence and potentially seizures; the Cardiopulmonary system, manifesting as tachycardia or respiratory depression; and the Gastrointestinal (GI) system, including nausea.

Overdose severity is classified based on the clinical presentation, with severe outcomes, such as profound respiratory or cardiac complications, indicating life-threatening toxicity.

Required Emergency Response

Immediate medical help is required upon any known or suspected overdose, or if severe symptoms such as difficulty breathing, loss of consciousness, or convulsions are observed. The official regulatory instruction is to call a poison control center or get medical help right away.

Management procedures detailed in regulatory texts focus on immediate supportive measures. These may include reducing absorption, maintaining a patent airway, continuous observation, and monitoring specific laboratory parameters or vital signs. If a specific antidote is available and listed in the official labeling, its administration may be mandated. Specific considerations for overdose management may apply to populations such as pediatric patients or individuals with hepatic impairment.

Therapeutic Uses of Structoflex

What Structoflex Treats: Main Uses and Benefits

Structoflex (Glucosamine hydrochloride) is a medication commonly used for the symptomatic relief of chronic joint issues, primarily focusing on managing the clinical manifestations of mild-to-moderate osteoarthritis of the knee. Its therapeutic scope is considered relevant for easing symptoms that interfere with daily functioning.


Easing Chronic Pain and Joint Stiffness

Structoflex is applied in situations involving certain distressing symptoms, addressing the core cluster of symptoms related to physical discomfort and functional stiffness that characterizes degenerative joint disease. The medicine is considered relevant for easing symptoms in mild-to-moderate osteoarthritis, as these conditions represent the primary therapeutic target.

Indications are relevant for addressing the key symptom patterns of the condition, including symptoms related to physical discomfort, functional stability, and stiffness. The treatment may assist with easing symptoms related to physical discomfort felt during movement and after rest. This contributes to improved day-to-day comfort during symptomatic periods.

“The symptomatic relief provided supports patients during difficult episodes by easing distress associated with chronic pain.”

Supporting Long-Term Functional Mobility

This medication is applied across domains where additional symptomatic support is needed in conditions where functional stability becomes affected by chronic joint degeneration. Used as part of a long-term management strategy, it contributes to easing the overall symptom load by supporting the management of pain and stiffness. Structoflex may assist with maintaining functional stability, which supports patients during episodes of heightened discomfort by easing distress.

Quick Fact: Relevant for Symptomatic Relief in Mild-to-Moderate Knee Osteoarthritis

Eligibility and Restrictions for Use

Structoflex (glucosamine) is an authorized medicine in certain regions for use only in the adult population and is subject to several official restrictions and contraindications as defined in regulatory documents.

Populations Who Must Not Use Structoflex

Use of Structoflex is contraindicated and must be avoided if the patient has:

  • Allergy Status: Known hypersensitivity (allergy) to the active substance (glucosamine) or any of the product's excipients.
  • Shellfish Allergy: Allergy to crustaceans (shellfish), as the active substance is extracted from them.

Populations with Restrictions or Requiring Caution

  • Age Profile: The medicine must not be used in children or adolescents below 18 years of age due to insufficient data to establish safety and efficacy in this group.
  • Pregnancy and Lactation: Use is not recommended during pregnancy or breastfeeding as safety has not been established in these physiological states.
  • Specific Conditions: Patients with impaired glucose tolerance (diabetes) require more frequent monitoring of blood glucose levels upon starting treatment. Caution and medical supervision are also required for individuals with asthma (as symptoms may worsen), renal (kidney) impairment, or hepatic (liver) impairment.

What should I know about interactions with other medicines?

Structoflex (glucosamine hydrochloride) has the potential to interact with certain other medications, which may alter their effects. Therefore, it is essential to inform a healthcare professional about all current medications, supplements, and herbal products before starting treatment.

Anticoagulants

Glucosamine may increase the effect of anticoagulants (medicines that thin the blood) such as warfarin, anisindione, and dicumarol. This combination could potentially increase the risk of bleeding or bruising, as evidenced by some reports of increased International Normalized Ratio (INR) values, a measure of blood clotting time. Close medical monitoring, including frequent INR checks, is strongly recommended if these medications are taken together, and the anticoagulant dose may need adjustment.

Other Medications

There is limited evidence suggesting that glucosamine may interact with certain chemotherapy drugs, specifically Topoisomerase II inhibitors (e.g., doxorubicin, teniposide), potentially decreasing their effectiveness. Additionally, for patients with diabetes taking antidiabetes drugs, blood glucose levels should be monitored more frequently upon initiating Structoflex, although most studies do not indicate a significant increase in blood sugar. The use of Structoflex alongside Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen or celecoxib, is generally considered safe, and in some cases, may offer synergistic pain relief, possibly reducing the required NSAID dose over time. However, any changes to existing therapy should only be made under medical guidance.

Mechanism of Action

️ Promoting Cartilage Structural Integrity

Glucosamine functions as a precursor that is essential for the biosynthesis of the macromolecules forming the cartilage matrix, notably Glycosaminoglycans (GAGs) and Proteoglycans. This precursor function supports the anabolic pathway of the chondrocytes, supporting the tissue's capacity for synthesis and metabolic balance and contributing to the structural integrity of the load-bearing cartilage.

️ Modulation of Catabolic and Inflammatory Pathways

The molecule exerts a key regulatory function by acting as an inhibitor of catabolic enzymes, specifically Matrix Metalloproteinases (MMPs). Furthermore, it modulates the inflammatory cascade by reducing the activation of the transcription factor NF-κB, which modulates the release of pro-inflammatory cytokines like Interleukin-1 beta (IL-1β). This mechanism mitigates the chronic inflammatory signaling and destructive enzymatic processes within the joint.

⏳ Mechanism-Dependent Time Course

The drug's function as a precursor and slow pathway modulator dictates a dependence on metabolic turnover and molecular accumulation. The mechanism requires time for component integration and pathway modulation, resulting in a characteristically delayed onset of the mechanism’s physiological effects. This time course reflects the underlying reliance on gradual metabolic and structural change.

Dosage and Administration Information

Official Administration Guidelines

Structoflex (Glucosamine hydrochloride) is intended for use via the oral route according to a specific regimen. The medicine is administered as a capsule and is not intended for acute pain management.


Standard Dosing and Schedule

The standard prescribed dose is 1500 mg Glucosamine hydrochloride per day. This dosage is typically achieved by taking two 750 mg capsules together. The required dosing frequency is once daily. The capsules must be swallowed whole with sufficient water, and administration is flexible, as intake is permitted **with or without meals.


Time-Dependent Protocol

As a symptomatic slow-acting drug, Structoflex is not designed to provide immediate relief. Symptomatic improvement may take several weeks of continuous administration. The official protocol requires a formal re-evaluation of treatment necessity if no relief is observed after 2 to 3 months of continuous use.


Population-Specific Use

Official prescribing information includes specific rules regarding certain populations. Use of the medicine is not recommended for individuals under the age of 18 years, as safety and efficacy have not been established in this group. For otherwise healthy older adults, no specific dose adjustment is required. Dosage adjustments for patients with renal or hepatic impairment have not been officially established due to a lack of dedicated studies in these populations.

These official instructions establish the standardized approach to administering the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies for Structoflex

Evidence for use in Mild to Moderate Knee Osteoarthritis

The active ingredient in Structoflex, Glucosamine hydrochloride, was evaluated in research for its role in mild to moderate osteoarthritis of the knee. The core body of evidence consists of Randomized Controlled Trials (RCTs) and large-scale Systematic Reviews that pool data from multiple individual trials. This research framework was applied in studies examining how symptoms change over time in conditions characterized by functional limitations of the knee.

Research examined how this medicine was observed in patients with mild to moderate forms of the condition. Studies examined outcomes related to physical discomfort and daily functioning or activity level, focusing on measurements of joint pain, stiffness, and mobility. These patient-reported outcomes describing perceived discomfort were used to monitor how patients reported their experience during the study period.

Findings were mixed when all different formulations of glucosamine were analyzed together in the scientific literature. However, studies focusing specifically on the Glucosamine hydrochloride formulation have consistently reported no observed difference in symptomatic patterns when compared directly to the placebo group. This research highlights changes measured during the study period, but studies reported no observed difference in symptomatic patterns when compared to inactive treatment.


What Clinical Trials Monitored

Clinical trials primarily focused on monitoring outcomes related to physical discomfort felt by patients. Researchers examined these changes using standardized measures, such as the WOMAC pain and function scales, which are applied in studies examining patient-reported experiences. Additionally, some long-term studies examined outcomes related to joint structural appearance, such as measuring changes in the joint space using X-rays.

What the Scientific Literature Reports as Uncertain

The overall evidence quality varies across studies concerning all forms of glucosamine. Certainty remains low regarding a clear and reliable symptomatic change when analyzing the Glucosamine hydrochloride formulation specifically. Multiple high-quality scientific reviews have reported that findings were mixed and that no observed difference was established over placebo for this specific formulation. These key limitations mean that the long-term effects are not fully established, and there is a recognized lack of observed difference from placebo in symptomatic relief for the Glucosamine hydrochloride form.

Key Studies & References TRANSPARENCY COMMITTEE - HAS (French Health Authority Opinion on Structoflex)

Frequently Asked Questions (FAQ)

Common questions about Structoflex (FAQ)

Q: Is Structoflex safe to take long-term?

Official documents indicate that the long-term effects of Structoflex are not fully established in all research. Due to its slow-acting nature, the treatment necessity is typically re-evaluated by a healthcare professional if no symptomatic changes are reported after two to three months of continuous use.

Q: Can Structoflex be taken with common pain relievers like Tylenol (acetaminophen)?

Some research evidence indicates that taking Structoflex along with acetaminophen (Tylenol) may potentially reduce the effectiveness of one or both medications. It is important to discuss the concurrent use of any pain relievers with a healthcare provider.

Q: Will Structoflex affect my sleep?

Official product information lists difficulty sleeping (insomnia) and drowsiness among the documented side effects. These effects are generally described as uncommon but may be noted when starting the medicine.

Q: How long do you typically stay on Structoflex treatment?

According to regulatory guidance, a healthcare professional typically re-evaluates the necessity of continued treatment if no symptomatic relief has been observed after two to three months. Beyond this check, there is no specific maximum duration of treatment defined in official documents for the general adult population.

Q: Does Structoflex interact with blood pressure medicine?

Official documents suggest that patients with high blood pressure (hypertension) should use Structoflex with caution. There are reports that glucosamine might slightly influence blood pressure in certain individuals, so medical monitoring by a healthcare provider is often suggested during use.

Q: What is the shelf life of Structoflex?

The specific shelf life for Structoflex is determined by the manufacturer and is listed as the expiry date (EXP) on the packaging. To maintain quality and stability, regulatory documents indicate that the medicine should not be used after this date.

Q: Is Structoflex widely studied internationally?

The active ingredient in Structoflex has been subject to detailed assessment by multiple major international regulatory bodies, including the European Medicines Agency (EMA) and the UK's MHRA. This confirms that the evidence and safety profile have been widely examined across global health authorities.

Q: Can Structoflex be taken with herbal supplements?

Official documents suggest informing a healthcare professional of all herbal products and supplements being used. This is due to the potential for unforeseen interactions, especially with herbal products that may influence processes like blood clotting.

Q: What happens if I miss a day of Structoflex?

The standard guidance found in the Patient Information Leaflet is that the general guidance is to take the missed dose as soon as possible. However, if it is nearly time for your next dose, skip the missed dose entirely and simply continue with your regular schedule. It is typically advised not to take a double dose to compensate.

Q: Is Structoflex the same as the supplement I saw online?

Structoflex is officially licensed as a prescription-only medicine (Rx) in some regions, confirming its standard of pharmaceutical quality and regulatory control. This status formally distinguishes it from the over-the-counter (OTC) food supplements containing glucosamine that are not subject to the same licensing requirements.

Q: Does Structoflex cause weight gain?

Official safety information and side effect profiles do not typically list weight gain as a documented reaction to Structoflex. If you experience unexpected weight changes, these may be discussed with a healthcare professional.

Q: Can Structoflex be taken while drinking alcohol?

Official regulatory documents advise patients to avoid the consumption of alcohol while taking Structoflex. This warning is in place because alcohol may potentially influence the effectiveness or the way the medicine works in the body.

Q: Are there any specific foods to avoid when taking Structoflex?

The official administration guidelines state that the capsule can be taken with or without meals. This indicates that there are no specific food restrictions or dietary changes mandated by regulatory documents when using this medicine.

Q: Is there a risk of dependency or addiction with Structoflex?

The active ingredient in Structoflex is not classified as a controlled substance by major regulatory bodies. Official product information does not contain any reports or warnings concerning the risk of dependency or addiction related to its use.

Q: Does Structoflex have any known warnings for people with heart issues?

Caution is advised for individuals with existing or at-risk cardiovascular conditions. Official post-marketing reports have documented side effects such as irregular heartbeats and swelling in the legs (oedema), which may be reviewed by a healthcare professional.

Q: Is Structoflex considered a controlled substance?

According to major international drug regulatory bodies, Structoflex (glucosamine) is not classified as a controlled substance. Its status is typically that of a prescription-only medicine in relevant regions.

Q: How is Structoflex eliminated from the body?

The active ingredient, Glucosamine, is rapidly absorbed and eliminated from the body with a short half-life. Its metabolic fate is closely related to its role as an endogenous substance—meaning it is naturally incorporated into body components like cartilage or broken down.

Q: What happens when you stop taking Structoflex suddenly?

Due to the medicine’s slow-acting, symptomatic nature of action, there are generally no acute withdrawal effects or sudden worsening of symptoms expected if the medicine is stopped abruptly. Any decision to stop treatment is typically made in consultation with a healthcare professional.

Q: Does Structoflex cause dry mouth?

Official side effect lists for Structoflex do not typically include dry mouth (Xerostomia) as a documented adverse reaction. If you experience this symptom, it is not associated with the known side-effect profile of this medicine.

Q: What does the box warning for Structoflex state?

Regulatory documents typically confirm that Glucosamine hydrochloride does not carry a Boxed Warning (also known as a Black Box Warning). This indicates that the medicine has not been officially assigned the most stringent safety-related warning by regulatory authorities like the US FDA.

How should Structoflex be stored and disposed of?

How to Store and Dispose of Structoflex

The storage and disposal of Structoflex (glucosamine hydrochloride) must comply with official regulatory guidelines to maintain its stability and ensure environmental protection.


Storage Requirements

Condition Requirement
Temperature Store below 25°C (77°F).
Container Store in the original package to protect the contents from moisture.
Stability Do not use the medicine after the expiry date (EXP) marked on the packaging.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

To protect the environment, the medicine must not be disposed of via household waste or by flushing it down wastewater. Unused or expired capsules should be taken to a pharmacist who will provide instructions on the proper handling and disposal of pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Structoflex found in:

A-Z Index: